Biotherapeutics

Conference microphone
#AI / data analytics / healthtech / informatics #Biotherapeutics #Events #Lab technology #SLAS2024

SLAS2024 update: How tech is reducing failure rates in trials

Be sure to attend the Ignite Theater at SLAS2024 in Boston on 5 and 6 February 2024. Focused on the theme ‘Innovation & technology: from lab to patient’, the DDW-curated programme, sponsored by Integra Biosciences and Hamamatsu Corporation, will feature presentations from experts… Read More

#News

Conference microphone
#AI / data analytics / healthtech / informatics #Biotherapeutics #Events #Lab technology #SLAS2024

SLAS2024 update: New tech accelerates drug development

The SLAS Ignite Theater ‘Innovation & technology: from lab to patient’, co-sponsored by Integra Biosciences and Hamamatsu Corporation, will take place at SLAS2024 in Boston on 5 and 6 February 2024. Developed by DDW in partnership with SLAS, the programme will feature leading… Read More

#News

Two scientists working in a lab
#Antibody discovery workflow #Biotherapeutics #Cell line development #Cell lines #Drug development #Large molecules

Advancements in upstream CLD for enhanced biotherapeutics production

This article is sponsored by Revvity. By Anis H Khimani, PhD, Senior Strategy Leader, Life Sciences strategy group, Revvity, Inc. Across the biotherapeutics workflow The landscape of large molecule drug development has evolved significantly in recent decades. As the significance of large molecules continues to broaden across diverse modalities, emphasis… Read More

#Exclusive Content

Lisbon skyline
#Biotherapeutics #CAR-T #Combination therapy #Drug targets #Engineered antibodies #Machine learning #PEGS Europe 2023

What to expect from PEGS Europe 2023: Day 2

Ahead of protein and antibody engineering conference PEGS Europe 2023 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. On Day 2, Wednesday 15 November 2023, the tracks include: Engineering antibodies, emerging targets and therapeutic approaches, advancing bispecifics and combination… Read More

#Exclusive Content

#AI #BioMap #Biotherapeutics #Collaboration #Sanofi

Collaboration to develop AI modules for biotherapeutics 

BioMap has entered a strategic collaboration with Sanofi to co-develop AI modules for biotherapeutic drug discovery, leveraging BioMap’s AI platform.  Traditional AI methods require vast amounts of labeled data to make accurate predictions. However, in life science, labeled data are often in short supply. BioMap’s foundational models… Read More

#News

Synthetic DNA
#Biotherapeutics #DNA #Synthetic biology #Synthetic DNA

Accelerating biotherapy and personalised medicine with long DNA

Listen to this article on the DDW Podcast: Matt Hill, Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development. With advanced technology and a growing understanding of the underlying biology, biotherapy development has evolved. Since 2010, investments in the… Read More

#Exclusive Content

#Bacteria #Biotherapeutics #Drug discovery #Gut microbiome

Harnessing the microbiome: The new frontier in drug discovery and testing 

Paul Denslow, CEO, Intus Bio, discusses how a new approach to tracking gut bacteria can revolutionse our understanding of the microbiome and bring about new discoveries for therapeutics.   It’s a long-held doctrine that there's no effective method to track the microbiome during drug research and development. This doctrine no longer… Read More

#Exclusive Content

Dravet syndrome
#Biotherapeutics #Dravet syndrome #Paediatrics

Bloom Science completes enrolment in Dravet Syndrome trial

Bloom Science, a clinical-stage, central nervous system (CNS) company focused on discovering and developing breakthrough therapeutics that target the Gut-Brain Axis, has completed enrolment in all four cohorts of healthy adult participants as part of its Phase I clinical trial.   Bloom is developing BL-001 for Dravet… Read More

#News

MRI of the brain
#Biotherapeutics #Bloom Science #epilepsy #Phase I trial

Live biotherapeutic could treat rare paediatric epilepsy

Bloom Science has completed enrolment of healthy adult participants as part of its Phase I clinical trial into BL-001 for Dravet syndrome, a rare paediatric epilepsy. BL-001 is an orally administered Live Biotherapeutic Product reverse translated from the positive clinical outcomes associated with the Ketogenic Diet… Read More

#News

#Anxiety disorder #Biotherapeutics #Neuroscience #Postpartum depression

Potential treatment for anxiety and postpartum depression 

PureTech Health, a clinical-stage biotherapeutics company, will advance therapeutic candidate LYT-300 (oral allopregnanolone) for the potential treatment of anxiety disorders and postpartum depression (PPD).    A social anxiety clinical trial in healthy volunteers is expected to begin in the first half of 2023, with results anticipated by the… Read More

#News

#Biotherapeutics #Funding #Probiotics #Start-ups

Start-up raises £1.3M to ‘revolutionise’ infant gut health

A female-led start-up developing a live biotherapeutic product to address infant gut needs, has raised £1.3M ($1.5M) in equity and grant funding.  BoobyBiome, founded by scientists Dr Lydia Mapstone, Dr Sioned Jones and Tara O’Driscoll, aims to develop a novel product for babies who do not have access to the… Read More

#Business & Investment #News #Start-up Zone

Applause
#Biotherapeutics #CDMO #Manufacturing

SGS Quay Pharma receives UK enterprise award 

Pharmaceutical contract development and manufacturing organisation (CDMO) SGS Quay Pharma has been recognised with a Queen’s Award in the UK for the strength of its export sales.   The CDMO won a Queen’s Award for Enterprise in the category of International Trade and was recognised for the… Read More

#News

#Assays #Biopharmaceuticals #Biotherapeutics #Drug development #Drug discovery

PerkinElmer releases assay kits for more effective biotherapeutics 

PerkinElmer has announced two ready-to-use HTRF and AlphaLISA no-wash assay kits designed to quickly and easily detect and quantify CHO HCP impurities during biopharmaceutical manufacturing.   Recombinant therapeutic proteins, such as monoclonal antibodies, some vaccines and other biologics, must be free of residual host cell protein (HCP) impurities… Read More

#News

#Biopharmaceuticals #Biotherapeutics #Drug development

Successful discovery and development collaboration continues  

Thermo Fisher Scientific and Symphogen are continuing their collaboration to provide biopharmaceutical discovery and development laboratories with innovative tools and streamlined workflows for efficient characterisation of complex therapeutic proteins.   Since the collaboration began in 2018, Symphogen has adopted instruments and software to improve data quality and processes… Read More

#News

#Biotechnology #Biotherapeutics

Nuclera announces expansion with new US subsidiary 

Nuclera, a UK-based biotech company, has opened a US subsidiary located in Boston, MA. This is designed to push Nuclera’s eProtein desktop bioprinter for biotherapeutics.  Dr Michael Chen, CEO and cofounder of Nuclera, said: “This site opening just outside one of the most important biotech markets is a big step towards Nuclera’s goal… Read More

#News

#Antibodies #Biotherapeutics #Covid variants #Covid-19 #Omicron

Antibody neutralises Omicron and Delta in live virus studies 

Revelar Biotherapeutics and Twist Bioscience have announced that RBT-0813 binds to and neutralises the Omicron and Delta variants of SARS-CoV-2 in live virus studies.   What is RBT-0813?  RBT-0813 is a bispecific antibody discovered by Twist Biopharma and licensed to Revelar Biotherapeutics that targets epitopes on the SARS-CoV-2 spike protein. Revelar has continued… Read More

#News #Trending News